Description: Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
Home Page: www.alzinova.com
Pepparedsleden 1
Mölndal,
431 83
Sweden
Phone:
46 7 08 46 79 75
Officers
| Name | Title |
|---|---|
| Dr. Kristina Torfgard | Chief Exec. Officer |
| Mr. Hakan Skogstrom | Chief Financial Officer |
| Dr. Anders Sandberg Ph.D. | Chief Scientific Officer |
| Dr. Anders Bylock | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3925 |
| Price-to-Sales TTM: | 6.6448 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |